S&P 500 Healthcare Sector SEC Filings — March 24, 2026

24-03-2026

Achieve Life Sciences reported Q4 and FY 2025 financial results, with cash and equivalents at $36.4M (up 6% from $34.4M prior year), but operating expenses surged 21% YoY to $14.7M in Q4 (driven by G&A doubling to $10.9M) and 41% to $54.9M annually, resulting in net losses of $14.7M and $54.7M respectively (up 19% and 37% YoY). The company advanced cytisinicline development with FDA NDA acceptance (PDUFA June 20, 2026), ORCA-OL trial completion (334 participants), and a U.S. manufacturing partnership with Adare Pharma Solutions for potential H1 2027 launch, while noting FDA observations at one manufacturer. Additional progress includes ORCA-3 publication in JAMA Internal Medicine and selection for FDA Commissioner's National Priority Voucher for vaping cessation.

• ·FDA observations at one cytisinicline NDA manufacturer for solid oral dose manufacturing, with remedial action plan in communication.
• ·Technology transfer to Adare Pharma Solutions commenced for U.S. manufacturing.
• ·Completed third-party logistics and specialty pharmacy partner selection process.
• ·Convertible debt: current portion $3.7M (2025) vs $0 (2024); non-current $11.2M vs $9.8M.
• ·Total assets $41.8M (2025) vs $38.6M (2024).

24-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 24, 2026, furnishing a press release announcing that its RAD division is expanding its presence in Alaska through a new ROSA order, which highlights the product's reliable performance in extreme weather conditions. The press release is attached as Exhibit 99.1 under Item 8.01 Other Events. No financial metrics or period-over-period comparisons were disclosed.

• ·Filing includes Exhibit 99.1: Press release dated March 24, 2026.
• ·Company address: 10800 Galaxie Avenue, Ferndale, Michigan 48220.
• ·Registrant is not an emerging growth company.

24-03-2026

News Corporation filed an 8-K on March 24, 2026, disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1 billion stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock. The filing attaches Exhibits 99.1 and 99.2 with the specific ASX disclosures but does not detail any new repurchase transactions in the body. Forward-looking statements note potential repurchases subject to market conditions and other factors.

24-03-2026

The 10-K annual report for JPMDB Commercial Mortgage Securities Trust 2019-COR6 assesses compliance with Regulation AB Item 1122 servicing criteria by Midland, CoreLogic, and other servicers. Applicable criteria were generally performed directly or via responsible vendors, with many others deemed N/A and no material non-compliance noted. The filing confirms adherence to transaction agreements across cash collection, investor reporting, and pool asset administration without highlighting any deficiencies.

• ·Filing date: March 24, 2026
• ·Multiple servicing criteria marked as N/A (e.g., back-up servicer requirements, investor remittances)
• ·Timeframes referenced include deposits/postings within 2 business days, reconciliations within 30 days, and resolution of reconciling items within 90 days

24-03-2026

The 10-K annual report for JPMCC Commercial Mortgage Securities Trust 2017-JP6, filed on March 24, 2026, details compliance assessments for servicing criteria under Regulation AB Item 1122 by servicer Midland and other asserting parties. Most applicable criteria across general servicing, cash collection, investor reporting, and pool asset administration are affirmed as performed directly (marked X) or by responsible vendors, with no material non-compliance noted. Several criteria are designated as N/A, inapplicable, or not performed by the asserting party, which is typical for structured ABS transactions.

24-03-2026

On March 23, 2026, Rose Marie Glazer and Adam Burk resigned from the Board of Directors of Corebridge Financial, Inc., effective immediately, with no disagreements on company matters. The resignations stem from AIG's $750 million share repurchase on February 17, 2026, reducing its ownership to approximately 5%, and AIG's waiver of board designation rights under the 2022 Separation Agreement (as amended in 2024). The Board plans to shrink from 13 to 11 authorized members.

• ·Share repurchase price: $30.42 per share
• ·Separation Agreement and Amendment filed as Exhibits 10.4 and 10.58 to Form 10-K on February 11, 2026
• ·Resignations approved following insurance regulator consent for AIG designee reduction

24-03-2026

Franklin Financial Services Corporation's DEF 14A proxy statement, filed March 24, 2026, outlines the virtual annual shareholder meeting on April 28, 2026, for electing four Class A directors for three-year terms, a non-binding advisory 'Say-on-Pay' vote on 2025 named executive officer compensation, and ratification of Crowe LLP as independent auditors for 2026. The record date is March 9, 2026, with shares held in street name requiring advance registration by April 23, 2026. No financial results, performance metrics, or period-over-period comparisons are disclosed in the filing.

• ·Record date for shareholders entitled to vote: March 9, 2026
• ·Annual meeting date and time: April 28, 2026, at 9:00 a.m. ET (virtual only at www.meetnow.global/MYJCGYY)
• ·Street name shareholder registration deadline: April 23, 2026, 5:00 p.m. ET
• ·Proxy materials mailed on or about March 24, 2026

24-03-2026

On March 19, 2026, the Board of Directors of New Mountain Guardian IV BDC, L.L.C. accepted the resignation of Kris Corbett as Chief Financial Officer and Treasurer, effective upon completion of a prudent transition expected by May 29, 2026. Mr. Corbett will continue serving in his role until the effective date, with no expressed disagreements on the Company's operations, policies, or practices. The filing was made on March 24, 2026.

• ·The Company is an emerging growth company.
• ·Entity Tax Identification Number: 88-1377220.
• ·Incorporated in Delaware.

24-03-2026

Absci Corporation reported Q4 and FY 2025 financial results showing flat Q4 revenue at $0.7M YoY but a 38% FY revenue decline to $2.8M, with R&D expenses rising 38% in Q4 to $25.3M and 27% FY to $81.4M driving net losses to widen slightly in Q4 to $29.6M and 12% FY to $115.2M. Positive clinical progress included dosing the first three cohorts in the ABS-201 HEADLINE Phase 1/2a trial with favorable safety data, unveiling supportive ex vivo data, and appointing Ransi Somaratne as Chief Medical Officer. Cash, cash equivalents, and marketable securities stood at $144.3M, sufficient to fund operations into H1 2028.

• ·Endometriosis prevalent in up to 10% of women worldwide.
• ·Preliminary ABS-201 safety/PK data expected H1 2026; interim proof-of-concept H2 2026; full proof-of-concept early 2027.
• ·Endometriosis Phase 2 trial initiation targeted Q4 2026.
• ·Conference call held March 24, 2026 at 4:30 p.m. ET.

24-03-2026

On March 19, 2026, the Board of Trustees of New Mountain Private Credit Fund accepted the resignation of Kris Corbett as Chief Financial Officer and Treasurer, effective upon completion of a transition to a successor by May 29, 2026. Mr. Corbett will remain in his role until the effective date and cited no disagreements with the company's operations, policies, or practices. No successor has been named yet.

24-03-2026

On March 19, 2026, the Board of Directors of New Mountain Guardian IV Income Fund, L.L.C. accepted the resignation of Kris Corbett as Chief Financial Officer and Treasurer, effective upon completion of a prudent transition expected by May 29, 2026. Mr. Corbett will remain in his role until the effective date, with no expressed disagreements on company operations, policies, or practices.

• ·Filing signed on March 24, 2026.
• ·Company formerly known as New Mountain Guardian IV Unlevered BDC, L.L.C. (name change: May 5, 2023).
• ·Company is an emerging growth company.
• ·Headquartered at 1633 Broadway, 48th Floor, New York, NY 10019.

24-03-2026

New Mountain Finance Corp announced on March 19, 2026, the acceptance of Kris Corbett's resignation as Chief Financial Officer and Treasurer, effective upon completion of a transition to a successor by May 29, 2026. Mr. Corbett will continue in his role until the effective date and expressed no disagreements with the company's operations, policies, or practices. No successor has been named yet, potentially introducing short-term leadership uncertainty.

• ·Filing submitted on March 24, 2026.
• ·Company securities: Common stock (NMFC) and 8.250% Notes due 2028 (NMFCZ) listed on NASDAQ Global Select Market.

24-03-2026

Medtronic's subsidiary MiniMed received FDA clearance for the next-generation MiniMed Flex insulin pump on March 18, 2026, ahead of schedule, enabling earlier commercialization funded partly by Blackstone. However, this triggers a $157M one-time charge in Q4 FY2026 ($0.08 per share impact based on 90% ownership), combined with $0.04 per share dilution from the March 9 MiniMed IPO, leading to lowered FY2026 non-GAAP EPS guidance of $5.50-$5.54 from prior $5.62-$5.66. FY2027 high single-digit EPS growth guidance remains unchanged.

• ·FDA clearance date: March 18, 2026
• ·MiniMed IPO closing date: March 9, 2026 (10% stake)
• ·Q4 FY2026 ends April 24, 2026
• ·Blackstone royalty: mid-to-high single digit % of net sales or minimum payments for first two years post-launch

24-03-2026

Horizon Space Acquisition II Corp. (HSPT) disclosed that SL Science Holding Limited (PubCo or SLBT) secured PIPE Financing commitments from investors for 780,000 PubCo Units at $10.00 each, expected to generate gross proceeds of $7.8M upon closing concurrently with the Business Combination. The Business Combination, agreed on May 9, 2025, involves mergers of HSPT and SL BIO Ltd. into subsidiaries of PubCo, with Units comprising one ordinary share and one Series A preferred share convertible to 1/3 ordinary share after six months, subject to a six-month lock-up. Forward-looking statements highlight risks including failure to close the deal or meet listing standards.

• ·PubCo Ordinary Shares and Series A Preferred Shares have par value of $0.00001 each.
• ·PIPE closing conditioned on prior or concurrent Business Combination closing.
• ·Subscription Agreements include customary representations, warranties, closing conditions, and indemnification for Securities Act liabilities.

24-03-2026

McEwen Inc. (MUX) filed an 8-K on March 24, 2026, disclosing under Regulation FD a press release dated March 23, 2026, reporting the mineral resource estimate for the Tartan Mine Project, furnished as Exhibit 99.1. No specific financial or operational metrics are detailed in the filing itself. Investors are directed to review the full press release for complete details.

• ·Filing includes standard cautionary statements on forward-looking information related to mineral resources.
• ·References Annual Report on Form 10-K for fiscal year ended December 31, 2025, for risk factors.

24-03-2026

AB Commercial Real Estate Private Debt Fund, LLC's total assets grew 30% YoY to $1.18B as of December 31, 2025, driven by mortgage loans receivable increasing 28% to $1.11B and members’ capital rising 16% to $398M amid 7.6M new common units issued. However, net income declined 12% YoY to $25.2M from $28.7M, with net interest income down 6% to $34.7M due to higher interest expense outpacing income growth, and net income per unit dropping 26% to $0.64. Distributions declared were 100% return of capital in both 2025 and 2024.

• ·Allowance for credit losses decreased to $4.4M from $6.1M YoY.
• ·Total operating expenses declined 10% YoY to $9.1M.
• ·Cash and cash equivalents increased to $21.3M from $10.9M.
• ·Repurchase agreement liability rose to $548.3M from $246.5M.
• ·Noncash conversion of Horton loan receivable to equity method investment: $17.4M.

24-03-2026

Flushing Financial Corporation (Nasdaq: FFIC), parent of Flushing Bank, declared a quarterly dividend of $0.22 per common share. The dividend is payable on April 24, 2026, to shareholders of record at the close of business on April 10, 2026. No changes to dividend policy or financial performance metrics were disclosed.

• ·Filed under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits), with Exhibit 99.1 being the press release dated March 24, 2026.

24-03-2026

Centene Corporation appointed Theodore Pienkos, 44, as Corporate Controller and Chief Accounting Officer effective March 18, 2026, with a base salary of $440,000 and target bonus of 60% of base salary. Previously the Deputy Corporate Controller, Mr. Pienkos succeeds Kate Casso, who transitions to Senior Vice President, Finance Operations and Innovation after over two decades with the company. The changes reflect the company's focus on intentional leadership development, with no family relationships or related party transactions involving Mr. Pienkos.

• ·Theodore Pienkos served as Deputy Corporate Controller since August 2024, Vice President of Finance & Accounting from August 2017 to August 2024, and other roles at Centene since March 2011; previously auditor at KPMG LLP from August 2004 to March 2011.
• ·Kate Casso served as Corporate Controller since April 2021.
• ·Mr. Pienkos holds a BA and MA in Accounting from the University of Northern Iowa.

24-03-2026

Artelo Biosciences, Inc. (ARTL) filed an S-1/A registration statement on March 24, 2026, for a public offering of common stock and pre-funded warrants, with no minimum proceeds required and placement agent fees of 7.0% plus 4.0% warrants. Interim Phase 2a CAReS trial results for ART27.13 showed strong efficacy with 6.38% mean body weight gain (max 18.5%) versus -5.42% loss (max -17.4%) in placebo for cancer anorexia patients (n=18 evaluable), alongside +4.23% lean body mass increase vs. -3.15% loss. Phase 1 SAD study for ART26.12 in 49 healthy subjects reported no drug-related adverse events, favorable safety, and linear pharmacokinetics.

• ·ART27.13 daily dose approved up to 1,300 micrograms; Phase 2a enrollment target: 40 evaluable patients (3:1 randomization).
• ·ART12.11 composition of matter patent enforceable until December 10, 2038 (granted/validated in 21 countries).
• ·ART26.12 IND cleared by FDA in July 2024; Phase 1 SAD study announced favorable in June 2025.
• ·CAReS first patient dosed April 2021; Phase 1b completed Q1 2023; Phase 2a initiated April 2023; interim announced September 3, 2025.

24-03-2026

Cingulate Inc. entered into an ATM Sales Agreement with A.G.P./Alliance Global Partners on March 24, 2026, enabling the sale of up to $100M in common stock shares through at-the-market offerings. At the Special Meeting of Stockholders on the same date, shareholders overwhelmingly approved Proposal 1 for the issuance of common stock upon conversion of Series A Convertible Preferred Stock and/or exercise of warrants (2,758,323 For, 97,941 Against, 12,372 Abstain). Proposal 2 to adjourn the meeting if needed was also approved but unnecessary (2,739,924 For, 116,691 Against).

• ·ATM Agreement termination upon sale of all Placement Shares or by mutual termination; no obligation to sell any shares.
• ·Sales conducted pursuant to Form S-3 shelf registration (File No. 333-292680) and prospectus supplement dated March 24, 2026.
• ·Proposal 1 and 2 had 0 broker non-votes; Proposal 1 had 12,372 abstentions, Proposal 2 had 12,021 abstentions.
• ·Company is an emerging growth company.

24-03-2026

Commercial Bancgroup, Inc. reported net income less non-controlling interest of $37.2M for FY 2025, up 18.4% YoY from $31.4M, driven by higher net interest income and lower noninterest expenses, while book value per share rose 14.6% to $20.83 and tangible book value per share increased 16.8% to $19.98. However, total assets declined slightly by 0.4% to $2.3B, asset quality slipped with nonperforming assets ratio rising to 0.28% from 0.26%, and allowance for credit losses to total loans decreased to 0.97% from 1.01%. Core deposits funded 91.6% of total deposits with a loan-to-deposit ratio of 103.2% as of Dec 31, 2025.

24-03-2026

Abra Financial Holdings, Inc. filed Form 425 on March 24, 2026, disclosing CEO Bill Barhydt's Cointelegraph interview amid its Business Combination Agreement with New Providence Acquisition Corp. III dated March 16, 2026. Barhydt highlighted his background in CIA, NASA, Netscape, Goldman Sachs, and early Bitcoin advocacy via a 2012 TED talk, emphasizing Bitcoin's solution to the double-spend problem for financial empowerment and remittances. No financial metrics or performance data were discussed.

• ·Business Combination Agreement dated March 16, 2026
• ·Interview aired March 24, 2026 at 11:00am ET on Cointelegraph's Chain Reaction show
• ·Barhydt's TED talk on Bitcoin in 2012 (mentioned as 2011 in parts)

24-03-2026

New Providence Acquisition Corp. III filed a Form 425 on March 24, 2026, disclosing an interview on Cointelegraph with Bill Barhydt, CEO of Abra Financial Holdings, Inc., the target in the previously announced Business Combination Agreement dated March 16, 2026. Barhydt detailed his background in tech and finance, including roles at CIA, NASA, Goldman Sachs, and Netscape, and his early Bitcoin involvement via a 2011-2012 TED talk, highlighting Bitcoin's solution to the double-spend problem for remittances like those post-Haiti earthquake. He discussed Bitcoin's evolution from peer-to-peer electronic cash to a store of value, aligning with self-sovereign individual principles, with no negative aspects or performance declines noted.

• ·Business Combination Agreement dated March 16, 2026
• ·Interview aired March 24, 2026 at 11:00am ET on Chain Reaction show
• ·Barhydt's TED talk on Bitcoin in 2011-2012
• ·Haiti earthquake remittances context approximately 13 years prior (circa 2013 reference)

24-03-2026

Thermo Fisher Scientific Inc. announced the completion of its acquisition of Clario Holdings, Inc. on March 24, 2026, via a press release attached as Exhibit 99.1. This event marks the finalization of the previously announced deal with no additional financial details or performance metrics disclosed in the filing.

24-03-2026

Earth Science Tech, Inc. (ETST) issued a press release on March 24, 2026, announcing the launch of MyOnlineConsultation.com, which finalizes a fully vertically integrated telehealth and pharmacy ecosystem. The release is filed as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. The filing was signed by CEO and Chairman Giorgio R. Saumat.

24-03-2026

COCA-COLA EUROPACIFIC PARTNERS plc (CCEP) disclosed ordinary share repurchases totaling 364,826 shares across US trading venues, London Stock Exchange, CBOE Europe Limited (CXE and BXE), and Aquis from March 17 to 20, 2026. Purchases on US venues ranged from 40,000 to 57,416 shares per day at VWAPs of $101.27 to $92.88 per share, while European venues saw varying volumes at GBP VWAPs of £70.11 to £76.00 per share. No repurchases occurred on some venues or days, with Aquis showing zero activity throughout.

• ·Highest prices paid: USD 101.90 (US, Mar 17), USD 99.995 (US, Mar 18), USD 96.67 (US, Mar 19), USD 95.33 (US, Mar 20)
• ·GBP highest prices: £76.40 (LSE, Mar 17), £75.70 (LSE, Mar 18), £72.90 (LSE, Mar 19), £71.70 (LSE, Mar 20)
• ·Zero repurchases on CBOE venues Mar 17-18 and Aquis all days

24-03-2026

Federal Home Loan Bank of New York announced the issuance of $210M in new callable bonds via Schedule A in its 8-K filing, with par amounts of $50M, $100M, $50M, and $10M. These fixed-rate bonds carry coupon rates ranging from 3.85% to 4.22% and maturities from March 2027 to June 2030, featuring optional principal redemption (primarily Bermudan style). No comparative performance data or changes from prior periods were provided.

• ·Trade dates: 3/18/2026 and 3/19-20/2026
• ·Settlement dates: 3/20/2026, 3/24/2026, 4/6/2026
• ·Next pay dates: 6/28/2026, 9/24/2026, 10/6/2026
• ·Next call dates: 6/28/2028, 9/24/2026, 7/6/2026, 3/24/2027
• ·Coupon rates: 3.91% (3130B9YK0), 3.85% (3130B9YM6), 4.22% (3130B9YT1), 3.95% (3130B9ZU7)

24-03-2026

The Federal Home Loan Bank of Cincinnati (FHLB) filed an 8-K under Item 2.03 reporting new Consolidated Bonds issuances totaling $425M in par value, with trade dates from March 18-20, 2026, for which it serves as the primary obligor. These fixed-rate callable bonds carry coupons of 3.830% to 4.035% and mature between 2027 and 2031. No period-over-period comparisons, financial impacts, or other metrics were provided in the filing.

• ·Bonds include Bermudan and European call styles with optional principal redemption.
• ·Next call/amort dates range from March 23, 2027 to September 30, 2026.
• ·Filing notes that par amounts may differ from GAAP financial statement amounts due to discounts, premiums, or concessions.

24-03-2026

JPMCC Commercial Mortgage Securities Trust 2016-JP2 announced a change in special servicer for the 100 East Pratt Mortgage Loan (5.4% of the asset pool as of cut-off date) and Four Penn Center Mortgage Loan (2.2% of the asset pool as of cut-off date), both serviced under the JPMDB Commercial Mortgage Securities Trust 2016-C2 PSA dated May 1, 2016. Argentic Services Company LP was removed as special servicer, with Midland Loan Services, a division of PNC Bank, National Association, appointed as successor effective March 24, 2026. No performance metrics or financial impacts were disclosed.

• ·Change effective as of March 24, 2026; Midland principal servicing office: 10851 Mastin Street, Building 82, Suite 300, Overland Park, Kansas 66210

24-03-2026

Effective March 24, 2026, Argentic Services Company LP was removed as special servicer for JPMDB Commercial Mortgage Securities Trust 2016-C2 pursuant to the Pooling and Servicing Agreement dated May 1, 2016, and Midland Loan Services, a division of PNC Bank, National Association, was appointed as successor special servicer, except with respect to the Quaker Bridge Mall Whole Loan, any Non-Serviced Mortgage Loans, and any Excluded Loans. Midland will handle servicing and administration of Specially Serviced Loans and REO Properties. No financial performance metrics or period-over-period changes were reported in the filing.

• ·Midland's principal servicing office: 10851 Mastin Street, Building 82, Suite 300, Overland Park, Kansas 66210.
• ·Original PSA filed as Exhibit 4.1 to Form 8-K on May 23, 2016.

24-03-2026

Cincinnati Bell Inc. filed an 8-K/A on March 24, 2026, amending its July 8, 2025, 8-K to report that Christi H. Cornette, Culture Operating Officer, entered into a Release of Claims dated March 19, 2026, in connection with her retirement. Under the agreement, Ms. Cornette will separate from employment effective April 1, 2026, and receive severance payments as required under her employment agreement. No specific financial terms beyond standard severance were disclosed.

• ·Original 8-K filed July 8, 2025, announcing retirement.
• ·Exhibit 10.1: Release of Claims attached.

24-03-2026

Federal Home Loan Bank of San Francisco reported under Item 2.03 the commitment to issue consolidated obligation bonds totaling $371.5M in principal (BANK PAR), for which it is the primary obligor, with trade dates of March 18 and March 20, 2026, maturities from 2027 to 2031, and fixed coupon rates ranging from 4.000% to 4.520%. These are callable Bermudan-style bonds sold through the Office of Finance, backed jointly by the eleven Federal Home Loan Banks but not by the U.S. government. The filing notes that such issuances are material overall but excludes short-term discount notes (≤1 year maturity) and does not reflect net changes in total outstanding obligations.

• ·Bonds feature Optional Principal Redemption call type and Bermudan call style.
• ·Next call dates range from 3/25/2027 to 9/30/2026.
• ·Schedule A excludes discount notes with maturity ≤1 year issued in ordinary course and any assumed obligations from other FHLBs exceeding 1-year remaining maturity.

24-03-2026

Circle Energy, Inc./NV (CRCE) reported zero revenues for the year ended December 31, 2025, with net loss increasing 15% YoY to $73,663 from $63,936 in 2024, and loss per share worsening to $(0.05) from $(0.04). Total assets declined 31% to $165,465 from $240,903, with cash dropping 42% to $111,201, though unproven oil and gas properties rose 14% to $39,500. Stockholders' equity fell to $164,763 from $238,426 amid higher operating cash usage of $75,823.

• ·General and administrative expenses increased to $73,663 in 2025 from $63,936 in 2024.
• ·No financing activities in 2025 or 2024; investing outflow of $5,000 for oil properties in 2025.
• ·Accumulated deficit reached $(282,300) as of December 31, 2025.
• ·Common stock: 1,530,000 shares issued and outstanding, unchanged YoY.